Airaksinen K, Butorina A, Pekkonen E, Nurminen J, Taulu S, Ahonen A, Schnitzler A, Mäkelä JP. Somatomotor mu rhythm amplitude correlates with rigidity during deep brain stimulation in Parkinsonian patients. Clinical Neurophysiology 2012; 123: 2012-2017.

Albrecht P, Henke N, Lehmann HC, Macht S, Hefter H, Goebels N, Mackenzie C, Rupprecht TA, Fingerle V, Hartung HP, Methner A. A case relapsing-remitting neuroborreliosis? Challenges in the differential diagnosis of recurrent myelitis. Case Reports in Neurology2012; 4: 47-53.

Albrecht P, Müller AK, Südmeyer M, Ferrea S, Ringelstein M, Cohn E, Aktas O, Dietlein T, Lappas A, Foerster A, Hartung HP, Schnitzler A, Methner A. Optical coherence tomography in parkinsonian syndromes. PLoS One 2012; 7: e34891.

Albrecht P, Müller AK, Ringelstein M, Finis D, Geerling G, Cohn E, Aktas O, Hartung HP, Hefter H, Methner A. Retinal neurodegeneration in Wilson's disease revealed by spectral domain optical coherence tomography. PLoS One 2012; 7: e49825.

Albrecht P, Bouchachia I, Zimmermann C, Hofstetter HH, Kovacs Z, Henke N, Lisak D, Issberner A, Lewerenz J, Maher P, Goebels N, Quasthoff K, Mausberg AK, Hartung HP, Methner A. Effects of dimethyl fumarate on neuroprotection and immunomodulation. Journal of Neuroinflammation 2012; 9: 163.

Albrecht P, Stettner M, Husseini L, Macht S, Jander S, Mackenzie C, Oesterlee U, Slotty P, Methner A, Hartung HP, Aktas O. An emboligenic pulmonary abscess leading to ischemic stroke and secondary brain abscess. BMC Neurology 2012; 12: 133.

Albrecht P, Ringelstein M, Müller AK, Keser N, Dietlein T, Lappas A, Foerster A, Hartung HP, Aktas O, Methner A. Degeneration of retinal layers in multiple sclerosis subtypes quantifiesd by optical coherence tomography. Multiple Sclerosis 2012; 18: 1422-1429.

Allert N, Schnitzler A, Sturm V, Maarouf M. Failure of long-term subthalamic nucleus stimulation corrected by additional pallidal stimulation in a patient with Parkinson's disease. Journal of Neurology 2012; 259: 1244-1246.

Arendt G, Nolting N. Neuro-AIDS in der cART-Ära. Fortschritte der Neurologie - Psychiatrie 2012; 80: 1-8.

Arendt G, Nolting T. AIDS - Psychiatrische Komorbiditäten. Neuropsychologie 2012; 1: 32-38.

Biermann-Ruben K, Miller A, Franzkowiak S, Finis J, Pollok B, Wach C, Südmeyer M, Jonas M, Thomalla G, Müller-Vahl K, Münchau A, Schnitzler A. Increased sensory feedback in Tourette syndrome. Neuroimage 2012; 63: 119-125.

Bosse F. Extrinsic cellular and molecular mediators of peripheral axonal regeneration. Cell & Tissue Research 2012; 349: 5-14.

Brandt AU, Zimmermann H, Kaufhold F, Promesberger J, Schippling S, Finis D, Aktas O, Geis C, Ringelstein M, Ringelstein EB, Hartung HP, Paul F, Kleffner I, Dörr J. Patterns of retinal damage facilitate differential diagnosis between Susac syndrome and MS. PLoS ONE2012; 7: e38741.

Bultynck G, Kiviluoto S, Henke N, Ivanova H, Schneider L, Rybalchenko V, Luyten T, Nuyts K, De Borggraeve W, Bezprozvanny I, Parys JB, De Smedt H, Missiaen L, Methner A. The C terminus of Bax inhibitor-1 forms a Ca2+-permeable channel pore. Journal of Biological Chemistry 2012; 287: 2544-2557.

Caloyeras JP, Zhang B, Wang C, Eriksson M, Fredrikson S, Beckmann K, Knappertz V, Pohl P, Hartung HP, Shah D, Miller JD, Sandbrink R, Lanius V, Gondek K, Russell MW. Cost-effectiveness analysis of interferon beta1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis. Clinical Therapy 2012; 34: 1132-1144.

Cohen JA, Reingold SC, Polman CH, Wolinsky JS; International Advisory Committee on Clinical Trials in Multiple Sclerosis. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurology 2012; 11: 467-476.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP; for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet 2012; 380: 1819-1828.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox E, Hartung HP; for the CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380: 1829-1839.

Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, Hartung HP. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis - associated endogenous retrovirus: a first-in-humans randomzied clinical study. Clinical Therapeutics 2012; 34: 2268-2278.

Dávalos A, Alvarez-Sabin J, Castillo J, Diez-Tejedor E, Ferro J, Martinez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J, Cobo E, Secades JJ [Jander S]; for the International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012; 380: 349-357.

Deng C, Hanna K, Bril V, Dalakas MC, Donofrio P, van Doorn PA, Hartung HP, Merkies IS. Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design. Journal of Neurology 2012; 259: 348-352.

Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurology 2012; 11: 420-428.

Fawcett JW, Schwab ME, Montani L, Brazda N, Müller HW. Defeating inhibition of regeneration by the glial scar and myelin components. In: Verhaagen J, McDonald J (eds.) Handbook of clinical Neurology. Volume 109 (3rd series) Spinal Cord Injury. Elsevier, Oxford, 2012, pp 503-522.

Fernandez O, Berger T, Hartung HP, Putzki N. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. Expert Review of Clinical Pharmacology 2012; 5: 649-665.

Finis J, Moczydlowski A, Pollok B, Biermann-Ruben K, Thomalla G, Heil M, Krause H, Jonas M, Schnitzler A, Münchau A. Echoes from childhood-imitation in Gilles de la Tourette Syndrome. Movement Disorders 2012; 27: 562-565.

Fischer D, Leibinger M. Promoting optic nerve regeneration. Progress in Retinal & Eye Research 2012; 31: 688-701.

Fischer D. Stimulating axonal regeneration of mature retinal ganglion cells and overcoming inhibitory signalling. Cell Tissue Research 2012; 349: 79-85.

Fledrich R, Schlotter-Weigel B, Schnizer TJ, Wichert SP, Stassart RM, Meyer zu Hörste G, Klink A, Weiss BG, Haag U, Walter MC, Rautenstrauss B, Paulus W, Rossner MJ, Sereda MW. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients. Brain 2012; 135: 72-87.

Florin E, Himmel M, Reck C, Maarouf M, Schnitzler A, Sturm V, Fink GR, Timmermann L. Subtype-specific statistical causalities in parkinsonian tremor. Neuroscience 2012; 210: 353-362.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators [Kieseier BC]. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine 2012; 367: 1087-1097.

Franzkowiak S, Pollok B, Biermann-Ruben K, Südmeyer M, Paszek J, Thomalla G, Jonas M, Orth M, Münchau A, Schnitzler A. Motor-cortical interaction in Gilles de la Tourette syndrome. PLoS One 2012; 7: e27850.

Freedman M, Metzig C, Kappos L, Polman C, Edan G, Hartung HP, Miller D, Montalban X, Yarden J, Spector L, Fire E, Dotan N, Schwenke S, Lanius V, Sandbrink R, Pohl C. Predictive nature of IgM anti-a-glucose serum biomarker for relapse activity EDSS progression in CIS patients: a BENEFIT study analysis. Multiple Sclerosis 2012; 18: 966-973.

Ganos C, Ogrzal T, Schnitzler A, Münchau A. The pathophysiology of echopraxia/echolalia: Revelance to Gilles de la Tourette syndrome. Movement Disorders 2012; 27: 1222-1229.

Gliem M, Mausberg AK, Lee JI, Simiantonakis I, van Rooijen N, Hartung HP, Jander S. Macrophages prevent hemorrhagic transformation in murine stroke models. Annals of Neurology 2012; 71: 743-752.

Gliem M, Hermsen D, van Rooijen N, Hartung HP, Jander S. Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice. Stroke 2012; 43: 3352-3357.

Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B; on behalf of the BEYOND Study Group. Neutralizing antibodies to interferon beta-Ib multiple sclerosis: A clinico-radiographic paradox in the BEYOND trial. Multiple Sclerosis Journal 2012; 18: 181-195.

Grimpe B. Deoxyribozymes and bioinformatics: complementary tools to investigate axon regeneration. Cell & Tissue Research 2012; 349: 181-200.

Haas J, Linker RA, Hartung HP, Meergans M, Ortler S, Tracik F. Fallstudie zum Konzept einer Therapieoption bei Multipler Sklerose vor Zulassung und Markteinführung. Nervenarzt 2012; 83: 1575-1581.

Hartung HP, Dihné M. Volume transmission-mediated encephalopathies: a possible new concept? Archives of Neurology 2012; 69: 315-321.

Hartung HP, Kieseier BC, Goodin D, Amason B, Comi G, Filippi M, Jeffery DR, Kappos L, et al. Variability in detection and quantification of interferon beta-1b-induced neutralizing antibodies. Journal of Neuroinflammation 2012; 9: 129.

Hartung HP, Keller-Stanislawski B, Hughes RA, Lehmann HC. Guillain-Barré-Syndrom nach Exposition mit Influenza. Nervenarzt 2012; 83: 714-730.

Hartung HP. Advances in the management of multiple sclerosis-related spasticity. Expert Review of Neurotherapeutics 2012; 12: 1.

Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H. Prospective analysis of neutralising antibody titres in secondary non-responders under continous treatment with a botulinumtoxin type A preparation free of complexing proteins - a single cohort 4-year follow-up study. BMJ Open 2012; 2: e000646.

Hefter H, Jost WH, Reissig A, Zakine B, Bakheit AM, Wissel J. Classification of posture in poststroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment? International Journal of Rehabilitation Research 2012; 35: 227-233.

Hefter H. Update Botulinumtoxintherapie. Nervenheilkunde 2012; 31: 685-691.

Hefter H, Blondin D, Kahlen U, Moll M, Antoch G, Schek J. CT-guided intramuscular botulinum toxin A injections into the deep anterior neck muscles in patients with pure antecaput or antecollis. Basal Ganglia 2012; 2: 97-101.

Hefter H, Kahlen U, Menge T, Rosenthal D, Moll M. Impact of posterior neck muscle treatment on cervical dystonia: Necessity to differentiate between abnormal positions of head and neck. Basal Ganglia 2012; 2: 103-107.

Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H. Prospective analysis of neutralizing antibody titres in secondary non-responders under continous treatment with a botulinumtoxin type A preparation free of complexing proteins - a single cohort 4-year follow-up study. BMJopen 2012; 2: e000646.

Heinen A, Tzekova N, Graffmann N, Torres KJ, Uhrberg M, Hartung HP, Küry P. Histone methyltransferase enhancer of zeste homolog 2 regulates Schwann cell differentiation. Glia2012; 60: 1696-1708.

Henke N, Albrecht P, Pfeiffer A, Toutzaris D, Zanger K, Methner A. Stromal interaction molecule 1 (STIM1) is involved in the regulation of mitochondrial shape and bioenergetics and plays a role in oxidative stress. Journal of Biological Chemistry 2012; 287: 42042-42052.

Hochmeister S, Romauch M, Bauer J, Seifert-Held T, Weissert R, Linington C, Hartung HP, Fazekas F, Storch MK. Re-expression of N-cadherin in remyelinating lesions of experimental inflammatory demyelination. Experimental Neurology 2012; 237: 70-77.

Hughes R, Hartung HP. Author's reply: Plasma exchange: are bigger studies necessarily better? Nature Reviews Neurology 2012; 8: 410.

Husseini L, Saleh A, Reifenberger G, Hartung HP, Kieseier BC. Inflammatory demyelinating brain lesions heralding primary CNS lymphoma. Canadian Journal of Neurological Sciences 2012; 39: 6-10.

Husseini L, Leussink VI, Warnke C, Hartung HP, Kieseier BC. Cannabinoide zur symptomatischen Therapie der Multiplen Sklerose. Nervenarzt 2012; 83: 695-704.

Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung HP. Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy. Clinical Immunology 2012; 142: 15-24.

Jadasz JJ, Aigner L, Rivera FJ, Küry P. The remyelination Philosopher's Stone: stem and progenitor cell therapies for multiple sclerosis. Cell & Tissue Research 2012; 349: 331-347.

Jadasz JJ, Rivera FJ, Taubert A, Kandasamy M, Sandner B, Weidner N, Aktas O, Hartung HP, Aigner L, Küry P. p57kip2 regulates glial fate decision in adult neural stem cells. Development 2012; 139: 3306-3315.

Jaerve A, Bosse F, Müller HW. SDF-1/CXCL12: its role in spinal cord injury. International Journal of Biochemistry & Cell Biology 2012; 44: 452-456.

Jaerve A, Müller HW. Chemokines in CNS injury and repair. Cell & Tissue Research 2012; 349: 229-248.

Jaerve A, Kruse F, Malik K, Hartung HP, Müller HW. Age-dependent modulation of cortical transcriptomes in spinal cord injury and repair. PLoS ONE 2012; 7: e49812.

Jaerve A, Schira J, Müller HW. Concise review: the potential of stromal cell-derived factor 1 and its receptors to promote stem cell functions in spinal cord repair. Stem Cells Translational Medicine 2012; 1: 732-739.

Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Multiple Sclerosis Journal 2012; 18: 1650-1652.

Jantzen SU, Ferrea ST, Langebner T, Gaebel W, Griese M, Arendt G, Dihné M. Late-stage neurosyphilis presenting with severe neuropsychiatric deficits - diagnosis, therapy and course of three patients. Journal of Neurology 2012; 259: 720-728.

Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Hartung HP, Aktas O, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Journal of Neuroinflammation 2012; 9: 14.

Kahlbrock N, Butz M, May ES, Brenner M, Kircheis G, Häussinger D, Schnitzler A. Lowered frequency and impaired modulation of gamma band oscillations in a bimodal attention task are associated with reduced critical flicker frequency. Neuroimage 2012; 61: 216-227.

Kamm CP, El-Koussy M, Humpert S, Findling O, von Bredow F, Burren Y, Schwegler G, Schött D, Donati F, Müller M, Goebels N, Müller F, Slotboom J, Tettenborn B, Kappos L, Naegelin Y, Mattle HP. Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. Journal of Neurology 2012; 259: 2401-2413.

Kieseier BC, Lehmann HC, Meyer zu Hörste G. Autoimmune diseases of the peripheral nervous system. Autoimmunity Reviews 2012; 11: 191-195.

Kieseier BC, Calabresi P. PEGylation of interferon b-1a: a promising strategy in multiple sclerosis. CNS Drugs 2012; 26: 205-214.

Kieseier BC, Pozzilli C. Assessing walking disability in multiple sclerosis. Multiple Sclerosis2012; 18: 914-924.

Kieseier BC, Stüve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, Ringelstein M, Turowski B, Aktas O, Antoch G, Hartung HP. Disease ameliorates with Tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular responses. Archives of Neurology 2012; 24: 1-4.

Kieseier BC. Therapeutischer Fortschritt - Chance und Herausforderung (Editorial). Der Neurologe & Psychiater 2012; 13: 3-4.

Kieseier BC. Guillain-Barré-Syndrom - IVIG Gabe nach vorangegangener Plasmaseparation. In: Stangel (ed.) Immunglobuline in der Neurologie in Fallbeispielen. Uni-med Verlag, Bremen, 2012, pp 44-46.

Kieseier BC. Chronisch inflammatorische demyelinisierende Polyradikuloneuritis (CIDP). In: Stangel (ed.) Immunglobuline in der Neurologie in Fallbeispielen. Uni-med Verlag, Bremen, 2012, pp 49-50.

Kiviluoto S, Schneider L, Luyten T, Vervliet T, Missiaen L, De Smedt H, Parys JB, Methner A, Bultynck G. Bax inhibitor-1 is a novel IP3 receptor-interacting and -sensitizing protein. Cell Death & Disease 2012; 3: 3367.

Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group. Failure of natalizumab to prevent relapses in neuromyelitis optica. Archives of Neurology 2012; 69: 239-245.

Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group. Is it too early to predict the failure of Natalizumab in NMO? - Reply. Archives of Neurology 2012; 69: 1085-1086.

Köhne A, Stettner M, Jangouk P, Dehmel T, Hartung HP, Lehmann HC, Kieseier BC. Fingolimod impedes Schwann cell-mediated myelination - Implications for the treatment of immune neuropathies? Archives of Neurology 2012; 69: 1280-1289.

Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, Hämäläinen P, Hartung HP, Krupp L, Penner IK, Reder AT, Benedict RH. Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS) Multiple Sclerosis Journal 2012; 18: 891-898.

Lehmann HC, Hughes RA, Kieseier BC, Hartung HP. Recent developments and future directions in Guillain-Barré syndrome. Journal of the Peripheral Nervous System 2012; 17: 57-70.

Lehmann HC, Macht S, Jander S, Hartung HP, Methner A. Guillain-Barré syndrome variant with prominent facial diplegia, limb paresthesia, and brisk reflexes. Journal of Neurology2012; 259: 370-371.

Lehmann HC, Hartung HP. Progress in untying the Gordian nodes of Ranvier in Guillain-Barré Syndrome. Experimental Neurology 2012; 235: 211-213.

Leibinger M, Andreadaki A, Fischer D. Role of mTOR in neuroprotection and axon regeneration after inflammatory stimulation. Neurobiology of Disease 2012; 46: 314-324.

Leussink VI, Husseini L, Wanrke C, Broussalis E, Hartung HP, Kieseier BC. Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Therapeutic Advances in Neurological Disorders 2012; 5: 255-266.

Lewerenz J, Maher P, Methner A. Regulation of xCT expression and system xc-function in neuronal cells. Amino Acids 2012; 42: 171-179.

Lewerenz J, Sato H, Albrecht P, Henke N, Noack R, Methner A, Maher P. Mutation ATF4 mediates resistance of neuronal cell lines against oxidative stress by inducing xCT expression. Cell Death & Differentiation 2012; 19: 847-858.

Lill CM, Schjeide BM, Akkad DA, Blaschke P, Winkelmann A, Gerdes LA, Hoffjan S, Luessi F, Dörner T, Li SC, Steinhagen-Thiessen E, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Kümpfel T, Kubisch C, Epplen JT, Zettl UK, Bertram L, Zipp F. Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample. Neurogenetics 2012; 13: 83-86.

Lill CM, Liu T, Schjeide BM, Roehr JT, Akkad DA, Damotte V, Alcina A, Ortiz MA; ANZgene Consortium [Hartung HP, Aktas O]. Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29000 subjects. Journal of Medical Genetics 2012; 49: 558-562.

Lindenberg R, Uhlig M, Scherfeld D, Schlaug G, Seitz RJ. Communication with emblematic gestures: shared and distinct neural correlates of expression and reception. Human Brain Mapping 2012; 33: 812-823.

Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis. Nature Reviews Neurology 2012; 8: 143-151.

Maurer MA, Rakocevic G, Leung CS, Quast I, Lukacisin M, Goebels N, Münz C, Wardemann H, Dalakas M, Lünemann JD. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. Journal of Clinical Investigation2012; 122: 1393-1402.

May ES, Butz M, Kahlbrock N, Hoogenboom N, Brenner M, Schnitzler A. Pre- and post-stimulus alpha activity shows differential modulation with spatial attention during the processing of pain. Neuroimage 2012; 62: 1965-1974.

Menge T, Kieseier BC, Warnke C, Aktas O, Hartung HP. Alemtuzumab: eine weitere Chance zur Therapie der Multiplen Sklerose. Nervenarzt 2012; 83: 487-501.

Menge T, Cree B, Saleh A, Waterboer T, Berthele A, Kalluri SR, Hemmer B, Aktas O, Hartung HP, Methner A, Kieseier BC. Neuromyelitis optica following human papilloma virus vaccination. Neurology2012; 79: 285-287.

Mentzer D, Prestel J, Adams O, Gold R, Hartung HP, Hengel H, Kieseier BC, Ludwig WD, Keller-Stanislawski B. Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. Journal of Neurology, Neurosurgery and Psychiatry 2012; 83: 927-933.

Müller HW, Sendtner M, Bähr M. Molecular basis of neural repair mechanisms. Editorial. Cell & Tissue Research Special Issue 2012; 349: 1-4.

Müller K, Bracht K, Schramm S, Seitz RJ. The facilitating effect of clinical hypnosis on motor imagery: an fMRI study. Behavioural Brain Research 2012; 231: 164-169.

Müller K, Bracht K, Prochnow D, Schramm S, Seitz RJ. Activation of thalamus in motor imagery results from gating by hypnosis. Neuroimage 2012; 66: 361-367.

Noack R, Frede S, Albrecht P, Henke N, Pfeiffer A, Knoll K, Dehmel T, Meyer zu Hörste G, Stettner M, Kieseier BC, Summer H, Golz S, Kochanski A, Wiedau-Pazos M, Arnold S, Lewerenz J, Methner A. Charcot-Marie-Tooth disease CMT4A: GDAP1 increases cellular glutathione and the mitochondrial membrane potential. Human Molecular Genetics 2012; 21: 150-162.

Nolting T, Lindecke A, Hartung HP, Koutsilieri E, Maschke M, Husstedt IW, Sopper S, Stüve O, Arendt G; and the German Competence Network HIV/AIDS. Cytokine levels in CSF and neuropsychological performance in HIV patients. Journal of Neurovirology 2012; 18: 157-161.

Oberwahrenbrock T, Schippling S, Ringelstein M, Kaufhold F, Zimmermann H, Keser N, Young KL, Harmel J, Hartung HP, Martin R, Paul F, Aktas O, Brandt AU. Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Multiple Sclerosis International 2012; 2012: 530305.

Oudega M, Chao OY, Avison DL, Bronson RT, Buchser WJ, Hurtado A, Grimpe B. Systemic administration of a deoxyribozyme to xylosyltransferase-1 mRNA promotes recovery after a spinal cord contusion injury. Experimental Neurology 2012; 237: 170-179.

Pedrosa DJ, Reck C, Florin E, Pauls KA, Maarouf M, Wojtecki L, Dafsari HS, Sturm V, Schnitzler A, Fink GR, Timmermann L. Essential tremor and tremor in Parkinson's disease are associated with distinct 'tremor clusters' in the ventral thalamus. Experimental Neurology 2012; 237: 435-443.

Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Pleimes D, Lanius V, Pohl C, Kappos L, Sandbrink R. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Multiple Sclerosis 2012; 18: 1466-1471.

Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Van-der-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieckmann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Multiple Sclerosis 2012; 18: 1721-1736.

Pollok B, Krause V, Martsch W, Wach C, Schnitzler A, Südmeyer M. Motor-cortical oscillations in early stages of Parkinson's disease. Journal of Physiology 2012; 590: 3203-3212.

Prochnow D, Höing B, Kleider R, Lindenberg R, Wittsack HJ, Schäfer R, Franz M, Seitz RJ. The neural correlates of affect reading: an fMRI study on faces and gestures. Behavioural Brain Research 2012; 237: 270-277.

Reck C, Maarouf M, Wojtecki L, Groiss SJ, Sturm V, Fink GR, Schnitzler A, Timmermann L. Clinical outcome of subthalamic stimulation in Parkinson's disease is improved by intraoperative multiple trajectories microelectrode recording. Journal of Neurological Surgery 2012; 73: 377-386.

Rieckmann P, Heidenreich F, Sailer M, Zettl UK, Zessack N, Hartung HP, Gold R. Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Therapeutic Advances in Neurological Disorders 2012; 5: 3-12.

Schira J, Gasis M, Estrada V, Hendricks M, Schmitz C, Trapp T, Kruse F, Kögler G, Wernet P, Hartung HP, Müller HW. Significant clinical, neuropathological and behavioural recovery from acute spinal cord trauma by transplantation of a well-defined somatic stem cell from human umbilical cord blood. Brain 2012; 135: 431-446.

Schnitzler A, Wojtecki L. Tiefe Hirnstimulation: Tremor und andere Bewegungsstörungen. In: Claßen/Schnitzler (eds.) Interventionelle Neurophysiologie. Thieme, 2012.

Schregel K, Wuerfel E, Garteiser P, Gemeinhardt I, Prozorovski T, Aktas O, Merz H, Petersen D, Wuerfel J, Sinkus R. Demyelination reduces brain parenchymal stiffness quantified in vivo by magnetic resonance elastography. PNAS 2012; 109: 6650-6655.

Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, Staugaitis SM, Welch W,Jilek S, Du Pasquier RA, Brück W, Toyka KV, Ransohoff RM, Wiendl H. Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control. Neurology 2012; 78: 458-467.

Schwarz CS, Ferrea S, Quasthoff K, Walter J, Görg B, Häussinger D, Schnitzler A, Hartung HP, Dihné M. Ammonium chloride influences in vitro-neuronal network activity. Experimental Neurology 2012; 235: 368-373.

Schwerdtfeger K, Mautes AE, Bernreuther C, Cui Y, Manville J, Dihné M, Blank S, Schachner M. Stress-resistant neural stem cells positively influence regional energy metabolism after spinal cord injury in mice. Journal of Molecular Neuroscience 2012; 46: 401-409.

Seibert J, Tracik F, Articus K, Spittler S. Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer's disease in daily practice. Neuropsychiatric Disease and Treatment 2012; 8: 141-147.

Seitz RJ, Angel HF. Processes of believing - a review and conceptual account. Reviews in the Neurosciences 2012; 23: 303-309.

Seitz RJ, Sukiennik J, Siebler M. Outcome after systemic thrombolysis is predicted by age and stroke severity - an open label experience with rtPA and tirofiban. Neurology International 2012; 4: e9.

Skodda S, Schlegel U, Südmeyer M, Schnitzler A, Wojtecki L. Effects of levodopa and deep brain stimulation on motor speech performance in Parkinson's disease. Basal Ganglia 2012; 2: 49-54.

Smolianov V, Dehmel T, Kieseier BC, Hemmer B, Hartung HP, Hofstetter HH. Ex vivo activation of naturally occurring IL-17-producing T cells does not require IL-6. Cytokine 2012; 58: 231-237.

Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis 2012; 18: 143-152.

Steffenhagen C, Dechant FX, Oberbauer E, Furtner T, Weidner N, Küry P, Aigner L, Rivera FJ. Mesenchymal stem cells prime proliferating adult neural progenitors towards an oligodendrocyte fate. Stem Cells & Development 2012; 21: 1838-1851.

Stettner M, Krämer G, Strauss A, Kvitkina T, Ohle S, Kieseier BC, Thelen P. Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. European Journal of Cancer Prevention 2012; 21: 55-64.

Stoeckel MC, Morgenroth F, Bütefisch CM, Seitz RJ. Differential grey matter changes in sensorimotor cortex related to exceptional fine motor skills. PLOS one 2012; 7: e51900.

Stroet A, Hemmelmann C, Starck M, Zettl U, Dörr J, Paul F, Flachenecker P, Fleischer V, Zipp F, Nückel H, Kieseier BC, Ziegler A, Gold R, Chan A. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Therapeutic Advances in Neurological Disorders 2012; 5: 75-79.

Stubbe-Dräger B, Deppe M, Mohammadi S, Keller SS, Kugel H, Gregor N, Evers S, Young P, Ringelstein EB, Arendt G, Knecht S, Husstedt IW; German Competence Network HIV/AIDS. Early microstructural white matter changes in patients with HIV: a diffusion tensor imaging study. BMC Neurology 2012; 12: 23.

Südmeyer M, Volkmann J, Wojtecki L, Deuschl G, Schnitzler A, Möller B. Tiefe Hirnstimulation - Erwartungen und Bedenken. Nervenarzt 2012; 83: 481-486.

Südmeyer M, Pieperhoff P, Ferrea S, Krause H, Groiss Sj, Elben S, Wojtecki L, Zilles K, Amunts K, Schnitzler A. Longitudinal deformation-based morphometry reveals spatio-temporal dynamics of brain volume changes in patients with corticobasal syndrome. PLoS One 2012; 7: e41873.

Südmeyer M, Wojtecki L, Schnitzler A. Teleneurologie beim M. Parkinson. Der Diabetologe2012; 8: 275-279.

Südmeyer M, Wojtecki L, Schnitzler A. Integrierte Versorgung des Morbus Parkinson. Aktuelle Neurologie 2012; 39: 475-479.

Torres KJ, Göttle P, Kremer D, Rivera JF, Aguirre-Cruz L, Corona T, Hartung HP, Küry P. Vinpocetine inhibits oligodendroglial precursor cell differentiation. Cellular Physiology & Biochemistry 2012; 30: 711-722.

Vanhoutte EK, Faber CG, Merkies IS; PeriNomS Study Group. MRC sum-score in the ICU: good reliability does not necessarily reflect "true reliability". Muscle & Nerve 2012; 45: 767-768.

Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van Koningsveld R, Cornblath DR, van der Kooi AJ, Cats EA, van den Berg LH, Notermans NC, van der Pol WL, Hermans MC, van der Beek NA, Gorson KC, Eurelings M, Engelsman J, Boot H, Meijer RJ, Lauria G, Tennant A, Merkies IS; PeriNomS Study Group. Modifying the medical research council grading system through Rasch analyses. Brain 2012; 135: 1639-1649.

Volkmann J, Wolters A, Kupsch A, Müller J, Kühn AA, Schneider GH, Poewe W, Hering S, Eisner W, Müller JU, Deuschl G, Pinsker MO, Skogseid IM, Roeste GK, Krause M, Tronnier V, Schnitzler A, Voges J, Nikkhah G, Vesper J, Classen J, Naumann M, Benecke R; DBS Study Group for Dystonia. Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurology 2012; 11: 1029-1038.

Walter J, Hartung HP, Dihné M. Interferon gamma and sonic hedgehog signaling are required to dysregulate murine neural stem/precursor cells. PLoS One 2012; 7: e43338.

Walter J, Dihné M. Species-dependent differences of embryonic stem cell-derived neural stem cells after Interferon gamma tretament. Frontiers in Cellular Neuroscience 2012; 6: 52.

Warnke C, Dehmel T, Posevitz-Fejfar A, Chan A, Berthele A, Schmidt S, Haas J, Kronsbein HC, Seitz F, Tackenberg B, Mäurer M, Gerbershagen K, Limmroth V, Adams O, Hartung HP, Gold R, Hemmer B, Wiendl H, Kieseier BC. Anti-JCV antibody prevalence in a German MS cohort. Multiple Sclerosis 2012; 18: 1054-1055.

Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP. Cladribine as a therapeutic option in multiple sclerosis. Clinical Immunology 2012; 142: 68-75.

Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken T, Buck D, Hartung HP, Holsboer F, Müller-Myhsok B, Hemmer B. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis. Pharmacogenomics Journal 2012; 12: 238-245.

Weber MS, Menge T, Lehmann-Horn K, Kronsbein HC, Zettl U, Sellner J, Hemmer B, Stüve O. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Current Pharmaceutical Design 2012; 18: 209-219.

Werdehausen R, Kremer D, Brandenburger T, Schlösser L, Jadasz J, Küry P, Bauer I, Aragón C, Eulenburg V, Hermanns H. Lidocaine metabolites inhibit glycine transporter 1: a novel mechanism for the analgesic action of systemic lidocaine? Anesthesiology 2012; 116: 147-158. Erratum in: Anesthesiology 2012; 116: 1404.

Wojtecki L, Ringelstein M, Südmeyer M, Schnitzler A. Doctor, is it Parkinson´s disease? Parkinsonism & Related Disorders 2012; 18: 113-114.

Wojtecki L, Südmeyer M, Schnitzler A. Multiple subcutaneous abscesses and necroses due to apomorphine pump treatment. Parkinsonism & Related Disorders 2012; 18: 1002.

Wojtecki L, Colosimo C, Fuentes R. Deep brain stimulation for movement disorders - A history of success and challenges to conquer. Frontiers in Integrative Neuroscience 2012; 6: 6.

Yuki N, Hartung HP. Guillain-Barré Syndrome. New England Journal of Medicine 2012; 366: 2294-2304.

MediathekInformation und Wissen
LageplanSo finden Sie uns